GSK delivers excellent Q2 with double digit sales growth

- **Adjusted operating profit growth:** 7%
- **Adjusted EPS:** 34.7p +6%
- **Total EPS from continuing operations:** 17.5p -58%
- **Regulatory approvals:** 3
- **Targeted acquisitions:** 2
- **Dividend:** 16.25p

**Specialty Medicines**
- £2.7bn +35%
- +13% excluding Covid

**Vaccines**
- £1.7bn +3%
- +24% excluding Covid

**General Medicines**
- £2.5bn +2%

Total sales: £6.9bn +13%

- Total sales
- Specialty Medicines
- Vaccines
- General Medicines

*Journalists/media see press release on www.gsk.com for full details on Q2 2022. Please read the cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures on pages 68 to 69 of the press release. References to growth are at constant exchange rates (CER) unless stated otherwise. Earnings per share have been adjusted to reflect the GSK Share Consolidation on 18 July 2022, see page 53 of the press release. The amounts presented above for continuing operations and Adjusted results excludes the Consumer Healthcare business discontinued operation. Affirivax acquisition is subject to customary closing conditions, including regulatory approval.*